Is Pfizer’s COVID-19 vaccine our pandemic game changer?
One big question is how we will transport and store a vaccine that needs to be kept at -70C
Interim analysis of data on a messenger RNA-based COVID-19 vaccine showing more than 90% efficacy in preventing infections is being hailed as promising by leading doctors.
Called BNT162b2, the vaccine apparently exceeds the 50% efficacy threshold set by the US Food and Drug Administration (FDA) in June, according to its makers, Pfizer and BioNTech.
They said protection from SARS-CoV-2 was achieved four weeks after initiation of the vaccination, which consists of a two-dose schedule.
The interim analysis, conducted by an independent data monitoring board, evaluated 94 confirmed cases of COVID-19 among more than 43,000 phase 3 trial participants.
